tetano
Editor, Senior Moderator
Eur J Med Chem
. 2023 Apr 17;254:115380.
doi: 10.1016/j.ejmech.2023.115380. Online ahead of print.
Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19
Fatema Hersi[SUP] 1 [/SUP], Anusha Sebastian[SUP] 2 [/SUP], Hamadeh Tarazi[SUP] 2 [/SUP], Vunnam Srinivasulu[SUP] 2 [/SUP], Ahmed Mostafa[SUP] 3 [/SUP], Abdou Kamal Allayeh[SUP] 4 [/SUP], Cong Zeng[SUP] 5 [/SUP], Ibrahim Y Hachim[SUP] 1 [/SUP], Shan-Lu Liu[SUP] 5 [/SUP], Imad A Abu-Yousef[SUP] 6 [/SUP], Amin F Majdalawieh[SUP] 6 [/SUP], Dana M Zaher[SUP] 1 [/SUP], Hany A Omar[SUP] 7 [/SUP], Taleb H Al-Tel[SUP] 8 [/SUP]
Affiliations
Abstract
The recent emergence of different SARS-CoV-2 variants creates an urgent need to develop more effective therapeutic agents to prevent COVID-19 outbreaks. Among SARS-CoV-2 essential proteases is papain-like protease (SARS-CoV-2 PLpro), which plays multiple roles in regulating SARS-CoV-2 viral spread and innate immunity such as deubiquitinating and deISG15ylating (interferon-induced gene 15) activities. Many studies are currently focused on targeting this protease to tackle SARS-CoV-2 infection. In this context, we performed a phenotypic screening using an in-house pilot compounds collection possessing a diverse skeleta against SARS-CoV-2 PLpro. This screen identified SIMR3030 as a potent inhibitor of SARS-CoV-2. SIMR3030 has been shown to exhibit deubiquitinating activity and inhibition of SARS-CoV-2 specific gene expression (ORF1b and Spike) in infected host cells and possessing virucidal activity. Moreover, SIMR3030 was demonstrated to inhibit the expression of inflammatory markers, including IFN-α, IL-6, and OAS1, which are reported to mediate the development of cytokine storms and aggressive immune responses. In vitro absorption, distribution, metabolism, and excretion (ADME) assessment of the drug-likeness properties of SIMR3030 demonstrated good microsomal stability in liver microsomes. Furthermore, SIMR3030 demonstrated very low potency as an inhibitor of CYP450, CYP3A4, CYP2D6 and CYP2C9 which rules out any potential drug-drug interactions. In addition, SIMR3030 showed moderate permeability in Caco2-cells. Critically, SIMR3030 has maintained a high in vivo safety profile at different concentrations. Molecular modeling studies of SIMR3030 in the active sites of SARS-CoV-2 and MERS-CoV PLpro were performed to shed light on the binding modes of this inhibitor. This study demonstrates that SIMR3030 is a potent inhibitor of SARS-CoV-2 PLpro that forms the foundation for developing new drugs to tackle the COVID-19 pandemic and may pave the way for the development of novel therapeutics for a possible future outbreak of new SARS-CoV-2 variants or other Coronavirus species.
Keywords: COVID-19; MERS-CoV; SARS-CoV-2; SARS-CoV-2 PLpro; Virucidal activity.
. 2023 Apr 17;254:115380.
doi: 10.1016/j.ejmech.2023.115380. Online ahead of print.
Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19
Fatema Hersi[SUP] 1 [/SUP], Anusha Sebastian[SUP] 2 [/SUP], Hamadeh Tarazi[SUP] 2 [/SUP], Vunnam Srinivasulu[SUP] 2 [/SUP], Ahmed Mostafa[SUP] 3 [/SUP], Abdou Kamal Allayeh[SUP] 4 [/SUP], Cong Zeng[SUP] 5 [/SUP], Ibrahim Y Hachim[SUP] 1 [/SUP], Shan-Lu Liu[SUP] 5 [/SUP], Imad A Abu-Yousef[SUP] 6 [/SUP], Amin F Majdalawieh[SUP] 6 [/SUP], Dana M Zaher[SUP] 1 [/SUP], Hany A Omar[SUP] 7 [/SUP], Taleb H Al-Tel[SUP] 8 [/SUP]
Affiliations
- PMID: 37075625
- DOI: 10.1016/j.ejmech.2023.115380
Abstract
The recent emergence of different SARS-CoV-2 variants creates an urgent need to develop more effective therapeutic agents to prevent COVID-19 outbreaks. Among SARS-CoV-2 essential proteases is papain-like protease (SARS-CoV-2 PLpro), which plays multiple roles in regulating SARS-CoV-2 viral spread and innate immunity such as deubiquitinating and deISG15ylating (interferon-induced gene 15) activities. Many studies are currently focused on targeting this protease to tackle SARS-CoV-2 infection. In this context, we performed a phenotypic screening using an in-house pilot compounds collection possessing a diverse skeleta against SARS-CoV-2 PLpro. This screen identified SIMR3030 as a potent inhibitor of SARS-CoV-2. SIMR3030 has been shown to exhibit deubiquitinating activity and inhibition of SARS-CoV-2 specific gene expression (ORF1b and Spike) in infected host cells and possessing virucidal activity. Moreover, SIMR3030 was demonstrated to inhibit the expression of inflammatory markers, including IFN-α, IL-6, and OAS1, which are reported to mediate the development of cytokine storms and aggressive immune responses. In vitro absorption, distribution, metabolism, and excretion (ADME) assessment of the drug-likeness properties of SIMR3030 demonstrated good microsomal stability in liver microsomes. Furthermore, SIMR3030 demonstrated very low potency as an inhibitor of CYP450, CYP3A4, CYP2D6 and CYP2C9 which rules out any potential drug-drug interactions. In addition, SIMR3030 showed moderate permeability in Caco2-cells. Critically, SIMR3030 has maintained a high in vivo safety profile at different concentrations. Molecular modeling studies of SIMR3030 in the active sites of SARS-CoV-2 and MERS-CoV PLpro were performed to shed light on the binding modes of this inhibitor. This study demonstrates that SIMR3030 is a potent inhibitor of SARS-CoV-2 PLpro that forms the foundation for developing new drugs to tackle the COVID-19 pandemic and may pave the way for the development of novel therapeutics for a possible future outbreak of new SARS-CoV-2 variants or other Coronavirus species.
Keywords: COVID-19; MERS-CoV; SARS-CoV-2; SARS-CoV-2 PLpro; Virucidal activity.